In last trading session, Bristol-Myers Squibb Co. (NYSE:BMY) saw 15.92 million shares changing hands with its beta currently measuring 0.45. Company’s recent per share price level of $43.70 trading at -$0.51 or -1.15% at ring of the bell on the day assigns it a market valuation of $88.58B. That closing price of BMY’s stock is at a discount of -58.12% from its 52-week high price of $69.10 and is indicating a discount of -0.07% from its 52-week low price of $43.73. Taking a look at company’s average trading volume volume of 16.10 million if we extend that period to 3-months.
Bristol-Myers Squibb Co. (NYSE:BMY) trade information
Upright in the red during last session for losing -1.15%, in the last five days BMY remained trading in the red while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $43.70 price level, adding 3.7% to its value on the day. Bristol-Myers Squibb Co.’s shares saw a change of -14.83% in year-to-date performance and have moved -2.24% in past 5-day. Bristol-Myers Squibb Co. (NYSE:BMY) showed a performance of -16.25% in past 30-days.
Bristol-Myers Squibb Co. (BMY) estimates and forecasts
Statistics highlight that Bristol-Myers Squibb Co. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -15.20% of value to its shares in past 6 months, showing an annual growth rate of -92.14% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 9.60% from the last financial year’s standing.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.51B for the same. And 15 analysts are in estimates of company making revenue of 11.19B in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.14% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -92.88% while estimates for its earnings growth in next 5 years are of -4.17%.
BMY Dividends
Bristol-Myers Squibb Co. is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
